The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Updates in CAR-T for non-Hodgkin lymphoma
In this video, Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, summarizes the key updates in CAR-T therapy for the treatment of non-Hodgkin lymphoma. Dr Collins highlights three studies from the 2021 ASH conference that focus on CAR-T therapy in first relapse for B-cell lymphoma: ZUMA-7, BELINDA, and TRANSFORM (NCT03391466, NCT03570892, NCT03575351). In his discussion, Dr Collins discusses and compares the results and subtle differences in these studies, including primary endpoints and outcomes. Following this, Dr Collins focuses his interest on the ZUMA-12 study (NCT03761056), explaining the methodology and results. This interview took place at the 63rd ASH Annual Meeting and Exposition, Atlanta, 2021.
